JP2024513881A - オキサゼピン化合物及びがんの治療におけるその使用 - Google Patents

オキサゼピン化合物及びがんの治療におけるその使用 Download PDF

Info

Publication number
JP2024513881A
JP2024513881A JP2023561271A JP2023561271A JP2024513881A JP 2024513881 A JP2024513881 A JP 2024513881A JP 2023561271 A JP2023561271 A JP 2023561271A JP 2023561271 A JP2023561271 A JP 2023561271A JP 2024513881 A JP2024513881 A JP 2024513881A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
compound according
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513881A5 (https=
Inventor
ルイス ジェー． ガザード，
サマンサ アリソン グリーン，
エリザベス エイチ． ケリー，
マシュー レオ ランドリー，
スシャント マルホトラ，
ベンジャミン デーヴィッド ラベッツ，
マイケル シウ，
ジャック アレキサンダー テレット，
ビンチン ウェイ，
スティーヴン ドー，
ユン－シン チョン，
リーミン チョン，
チエンフォン シン，
ミンタオ ホー，
クオション ウー，
インレイ スン，
チェン シャオ，
アイチュン ルー，
ユイライ チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024513881A publication Critical patent/JP2024513881A/ja
Publication of JP2024513881A5 publication Critical patent/JP2024513881A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023561271A 2021-04-08 2022-04-06 オキサゼピン化合物及びがんの治療におけるその使用 Pending JP2024513881A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/085959 2021-04-08
CN2021085959 2021-04-08
PCT/US2022/023573 WO2022216762A1 (en) 2021-04-08 2022-04-06 Oxazepine compounds and uses thereof in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024513881A true JP2024513881A (ja) 2024-03-27
JP2024513881A5 JP2024513881A5 (https=) 2025-04-02

Family

ID=81387302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561271A Pending JP2024513881A (ja) 2021-04-08 2022-04-06 オキサゼピン化合物及びがんの治療におけるその使用

Country Status (12)

Country Link
US (1) US20240383915A1 (https=)
EP (1) EP4320132A1 (https=)
JP (1) JP2024513881A (https=)
KR (1) KR20230167386A (https=)
CN (1) CN117083279A (https=)
AR (1) AR125304A1 (https=)
AU (1) AU2022254674A1 (https=)
BR (1) BR112023020773A2 (https=)
CA (1) CA3215949A1 (https=)
MX (1) MX2023011873A (https=)
TW (1) TWI868441B (https=)
WO (1) WO2022216762A1 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
AU2023231139A1 (en) 2022-03-11 2024-09-05 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
IL318647A (en) 2022-08-05 2025-03-01 Kumquat Biosciences Inc Heterocyclic compounds and their uses
AU2023320914A1 (en) * 2022-08-11 2025-02-27 Beone Medicines I Gmbh Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2024041573A1 (en) * 2022-08-25 2024-02-29 Zai Lab (Shanghai) Co., Ltd. Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
AU2023363515A1 (en) * 2022-10-18 2025-04-17 Idience Co., Ltd. Novel triheterocyclic compounds
JP2025535367A (ja) * 2022-10-19 2025-10-24 ジェネンテック， インコーポレイテッド ６－アザ部分を含むオキサゼピン化合物およびその使用
TW202430179A (zh) 2022-11-21 2024-08-01 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑
WO2024153180A1 (zh) * 2023-01-18 2024-07-25 上海艾力斯医药科技股份有限公司 杂环类化合物、其药物组合物及其用途
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
WO2024197503A1 (en) * 2023-03-27 2024-10-03 Nikang Therapeutics , Inc. Tricyclic derivatives as kras inhibitors
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN121194980A (zh) * 2023-05-16 2025-12-23 和记黄埔医药（上海）有限公司 三环类化合物及其用途
CN121605110A (zh) * 2023-06-06 2026-03-03 金橘生物科技公司 取代杂环化合物及其用途
CN121263417A (zh) * 2023-06-30 2026-01-02 金橘生物科技公司 取代的稠合三环胺化合物及其作为ras抑制剂的用途
CN116903499B (zh) * 2023-07-11 2025-05-30 上海应用技术大学 无水氟磺酰基二氟乙酸铜盐及其制备方法与应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025038936A1 (en) 2023-08-17 2025-02-20 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025096738A1 (en) * 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
WO2025111586A1 (en) 2023-11-22 2025-05-30 Genentech, Inc. Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d
WO2025130912A1 (zh) * 2023-12-19 2025-06-26 正大天晴药业集团股份有限公司 三并环类化合物及其医药用途
WO2025167948A1 (zh) * 2024-02-06 2025-08-14 上海齐鲁制药研究中心有限公司 嘧啶并大环类kras抑制剂
WO2025168072A1 (en) * 2024-02-08 2025-08-14 Beigene (Suzhou) Co., Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019215203A1 (en) * 2018-05-08 2019-11-14 Astrazeneca Ab Tetracyclic heteroaryl compounds
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2020178282A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP6832430B2 (ja) * 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519589A (ja) * 2017-05-11 2020-07-02 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
WO2019215203A1 (en) * 2018-05-08 2019-11-14 Astrazeneca Ab Tetracyclic heteroaryl compounds
WO2020178282A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
CN112574224A (zh) * 2019-09-30 2021-03-30 上海迪诺医药科技有限公司 Kras g12c抑制剂及其应用

Also Published As

Publication number Publication date
CN117083279A (zh) 2023-11-17
TW202304934A (zh) 2023-02-01
KR20230167386A (ko) 2023-12-08
MX2023011873A (es) 2023-10-17
AR125304A1 (es) 2023-07-05
US20240383915A1 (en) 2024-11-21
WO2022216762A1 (en) 2022-10-13
EP4320132A1 (en) 2024-02-14
CA3215949A1 (en) 2022-10-13
BR112023020773A2 (pt) 2024-01-30
TWI868441B (zh) 2025-01-01
AU2022254674A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US12338256B2 (en) Aza-tetracyclic oxazepine compounds and uses thereof
JP2024513881A (ja) オキサゼピン化合物及びがんの治療におけるその使用
TWI824405B (zh) 四環氧氮呯化合物及其用途
JP7374960B2 (ja) 縮合環化合物
JP2025535367A (ja) ６－アザ部分を含むオキサゼピン化合物およびその使用
RU2783706C1 (ru) Соединения с конденсированными кольцами
HK40099028A (zh) 氧氮杂䓬化合物及其在癌症治疗中的用途
WO2025194134A1 (en) Linearly substituted oxazepin-5-one kras-g12d inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260403